NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Fundamental Analysis

Europe • Euronext Oslo • OSL:NYKD • NO0010714785

2.932 NOK
+0 (+0.07%)
Last: Feb 4, 2026, 07:00 PM
Fundamental Rating

3

Overall NYKD gets a fundamental rating of 3 out of 10. We evaluated NYKD against 84 industry peers in the Biotechnology industry. While NYKD seems to be doing ok healthwise, there are quite some concerns on its profitability. NYKD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • NYKD had negative earnings in the past year.
  • In the past year NYKD has reported a negative cash flow from operations.
  • In the past 5 years NYKD reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: NYKD reported negative operating cash flow in multiple years.
NYKD.OL Yearly Net Income VS EBIT VS OCF VS FCFNYKD.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

  • NYKD has a Return On Assets of -10.41%. This is in the better half of the industry: NYKD outperforms 64.29% of its industry peers.
  • The Return On Equity of NYKD (-11.09%) is better than 71.43% of its industry peers.
Industry RankSector Rank
ROA -10.41%
ROE -11.09%
ROIC N/A
ROA(3y)-20.49%
ROA(5y)0.02%
ROE(3y)-25.42%
ROE(5y)0.53%
ROIC(3y)N/A
ROIC(5y)N/A
NYKD.OL Yearly ROA, ROE, ROICNYKD.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

  • NYKD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NYKD.OL Yearly Profit, Operating, Gross MarginsNYKD.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

6

2. Health

2.1 Basic Checks

  • NYKD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NYKD remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, NYKD has more shares outstanding
  • The debt/assets ratio for NYKD has been reduced compared to a year ago.
NYKD.OL Yearly Shares OutstandingNYKD.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
NYKD.OL Yearly Total Debt VS Total AssetsNYKD.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • NYKD has an Altman-Z score of 9.23. This indicates that NYKD is financially healthy and has little risk of bankruptcy at the moment.
  • NYKD's Altman-Z score of 9.23 is amongst the best of the industry. NYKD outperforms 85.71% of its industry peers.
  • A Debt/Equity ratio of 0.02 indicates that NYKD is not too dependend on debt financing.
  • NYKD has a better Debt to Equity ratio (0.02) than 76.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 9.23
ROIC/WACCN/A
WACC8.54%
NYKD.OL Yearly LT Debt VS Equity VS FCFNYKD.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • NYKD has a Current Ratio of 17.14. This indicates that NYKD is financially healthy and has no problem in meeting its short term obligations.
  • NYKD's Current ratio of 17.14 is amongst the best of the industry. NYKD outperforms 98.81% of its industry peers.
  • A Quick Ratio of 17.14 indicates that NYKD has no problem at all paying its short term obligations.
  • NYKD has a better Quick ratio (17.14) than 98.81% of its industry peers.
Industry RankSector Rank
Current Ratio 17.14
Quick Ratio 17.14
NYKD.OL Yearly Current Assets VS Current LiabilitesNYKD.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

  • The earnings per share for NYKD have decreased by -0.18% in the last year.
  • Looking at the last year, NYKD shows a very strong growth in Revenue. The Revenue has grown by 72.62%.
  • NYKD shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -36.54% yearly.
EPS 1Y (TTM)-0.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.67%
Revenue 1Y (TTM)72.62%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • NYKD is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -66.63% yearly.
  • NYKD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 184.95% yearly.
EPS Next Y70.24%
EPS Next 2Y18.52%
EPS Next 3Y14.21%
EPS Next 5Y-66.63%
Revenue Next Year-72.85%
Revenue Next 2Y-41.42%
Revenue Next 3Y52.25%
Revenue Next 5Y184.95%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NYKD.OL Yearly Revenue VS EstimatesNYKD.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 2031 1B 2B 3B 4B 5B
NYKD.OL Yearly EPS VS EstimatesNYKD.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • NYKD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NYKD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYKD.OL Price Earnings VS Forward Price EarningsNYKD.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYKD.OL Per share dataNYKD.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NYKD's earnings are expected to grow with 14.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.52%
EPS Next 3Y14.21%

More info and screens

6

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 32.98%, NYKD is a good candidate for dividend investing.
  • NYKD's Dividend Yield is rather good when compared to the industry average which is at 0.66. NYKD pays more dividend than 100.00% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, NYKD pays a better dividend.
Industry RankSector Rank
Dividend Yield 32.98%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

DPN/A
EPS Next 2Y18.52%
EPS Next 3Y14.21%
NYKD.OL Yearly Income VS Free CF VS DividendNYKD.OL Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

More info and screens

NYKODE THERAPEUTICS ASA

OSL:NYKD (2/4/2026, 7:00:00 PM)

2.932

+0 (+0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24
Earnings (Next)02-25
Inst Owners12.46%
Inst Owner ChangeN/A
Ins Owners1.64%
Ins Owner ChangeN/A
Market Cap957.44M
Revenue(TTM)6.77M
Net Income(TTM)-11.01M
Analysts42.22
Price Target2.24 (-23.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 32.98%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-58.88%
PT rev (3m)-57.28%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-16.67%
EPS NY rev (3m)36.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.61
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 1
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-1.05
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0.2
BVpS2.94
TBVpS2.94
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.41%
ROE -11.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.49%
ROA(5y)0.02%
ROE(3y)-25.42%
ROE(5y)0.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.22%
Cap/Sales 1.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.14
Quick Ratio 17.14
Altman-Z 9.23
F-Score5
WACC8.54%
ROIC/WACCN/A
Cap/Depr(3y)80.08%
Cap/Depr(5y)78.32%
Cap/Sales(3y)17.63%
Cap/Sales(5y)11.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.67%
EPS Next Y70.24%
EPS Next 2Y18.52%
EPS Next 3Y14.21%
EPS Next 5Y-66.63%
Revenue 1Y (TTM)72.62%
Revenue growth 3Y-36.54%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-72.85%
Revenue Next 2Y-41.42%
Revenue Next 3Y52.25%
Revenue Next 5Y184.95%
EBIT growth 1Y55.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.65%
EBIT Next 3Y18.13%
EBIT Next 5Y-60.17%
FCF growth 1Y43.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.92%
OCF growth 3YN/A
OCF growth 5YN/A

NYKODE THERAPEUTICS ASA / NYKD.OL FAQ

What is the ChartMill fundamental rating of NYKODE THERAPEUTICS ASA (NYKD.OL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NYKD.OL.


What is the valuation status of NYKODE THERAPEUTICS ASA (NYKD.OL) stock?

ChartMill assigns a valuation rating of 0 / 10 to NYKODE THERAPEUTICS ASA (NYKD.OL). This can be considered as Overvalued.


What is the profitability of NYKD stock?

NYKODE THERAPEUTICS ASA (NYKD.OL) has a profitability rating of 1 / 10.


What is the earnings growth outlook for NYKODE THERAPEUTICS ASA?

The Earnings per Share (EPS) of NYKODE THERAPEUTICS ASA (NYKD.OL) is expected to grow by 70.24% in the next year.